Citation Impact
Citing Papers
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro
2006 StandoutNobel
Complete Replication of Hepatitis C Virus in Cell Culture
2005 StandoutScienceNobel
Characterization of a canine homolog of hepatitis C virus
2011 StandoutNobel
Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients
2007 StandoutNobel
Side effects of therapy of hepatitis C and their management
2002
To Interfere and to Anti-interfere: The Interplay Between Hepatitis C Virus and Interferon
2002
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
2005 Standout
Hepatitis C virus infection affects the brain—evidence from psychometric studies and magnetic resonance spectroscopy
2004
Primary Biliary Cirrhosis
2005
Chronic inflammation in the etiology of disease across the life span
2019 Standout
Hepatitis C virus genotype 3: a genotype that is not ‘easy-to-treat’
2014
euHCVdb: the European hepatitis C virus database
2006 StandoutNobel
Unravelling hepatitis C virus replication from genome to function
2005 StandoutNatureNobel
Cognitive impairment in primary biliary cirrhosis
2008
Liver Injury and Disease Pathogenesis in Chronic Hepatitis C
2013
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver
2014 Standout
Hepatitis B virus infection
2009 Standout
Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection
2006 StandoutNobel
Characteristics of Minimal Hepatic Encephalopathy
2004
Hepatitis C virus host cell entry
2012
Rapid Regulation of Depression-Associated Genes in a New Mouse Model Mimicking Interferon-α-Related Depression in Hepatitis C Virus Infection
2014
Cell culture–produced hepatitis C virus does not infect peripheral blood mononuclear cells
2008 StandoutNobel
Molecular and Bioinformatic Evidence of Hepatitis C Virus Evolution in Brain
2008
Neurological and neuropsychiatric syndromes associated with liver disease
2005
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells
2006 StandoutNobel
Characterization of host‐range and cell entry properties of the major genotypes and subtypes of hepatitis C virus†
2005
Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence
2006
Antagonistic expression of hepatitis C virus and alpha interferon in lymphoid cells during persistent occult infection
2007
Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C
2005
Hepatitis C Virus Entry
2007 StandoutNobel
Interferons α and λ Inhibit Hepatitis C Virus Replication With Distinct Signal Transduction and Gene Regulation Kinetics
2006 StandoutNobel
Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B
2004
A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans
2013 StandoutNobel
Pathogenesis, diagnosis and management of hepatitis C
2000
Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
2016
Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations
2004
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
2011 Standout
The way forward in HCV treatment — finding the right path
2007 StandoutNobel
Hepatocellular carcinoma
2022 Standout
Mathematical modeling of primary hepatitis C infection: Noncytolytic clearance and early blockage of virion production
2005 StandoutNobel
Replication of hepatitis C virus
2007 StandoutNobel
Hepatitis C Virus RNA Functionally Sequesters miR-122
2015 StandoutNobel
The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection
2017
Side effects of therapy of hepatitis C and their management
2002
Liver-Directed Gamma Interferon Gene Delivery in Chronic Hepatitis C
2005 StandoutNobel
Induction of Broad CD4+and CD8+T-Cell Responses and Cross- Neutralizing Antibodies against Hepatitis C Virus by Vaccination with Th1-Adjuvanted Polypeptides Followed by Defective Alphaviral Particles Expressing Envelope Glycoproteins gpE1 and gpE2 and Nonstructural Proteins 3, 4, and 5
2008 StandoutNobel
Hepatocellular Carcinoma
2019 Standout
RTP4 inhibits IFN-I response and enhances experimental cerebral malaria and neuropathology
2020 StandoutNobel
Flying Under the Radar: The Immunobiology of Hepatitis C
2006 StandoutNobel
Combination of a Hepatitis C Virus NS3-NS4A Protease Inhibitor and Alpha Interferon Synergistically Inhibits Viral RNA Replication and Facilitates Viral RNA Clearance in Replicon Cells
2004
Therapy for hepatitis C genotype 3: moving forward
2015
The Infectious Etiology of Alzheimer’s Disease
2017
Sofosbuvir and ribavirin in adolescents 12‐17 years old with hepatitis C virus genotype 2 or 3 infection
2017
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
2002 Standout
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C
2005 StandoutNobel
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
2012 StandoutNobel
Mechanisms, diagnosis and management of hepatic encephalopathy
2010
High-Avidity Monoclonal Antibodies against the Human Scavenger Class B Type I Receptor Efficiently Block Hepatitis C Virus Infection in the Presence of High-Density Lipoprotein
2007 StandoutNobel
Quasispecies Heterogeneity within the E1/E2 Region as a Pretreatment Variable during Pegylated Interferon Therapy of Chronic Hepatitis C Virus Infection
2005
Direct‐acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local‐regional therapy or liver transplant waitlist dropout
2018
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Mathematical Modeling of Subgenomic Hepatitis C Virus Replication in Huh-7 Cells
2006 StandoutNobel
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Hepatitis C Virus Neuroinvasion: Identification of Infected Cells
2008
Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus
2014 StandoutNobel
Viral persistence, liver disease, and host response in a hepatitis C–like virus rat model
2017 StandoutNobel
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Time- and Temperature-Dependent Activation of Hepatitis C Virus for Low-pH-Triggered Entry
2006 StandoutNobel
Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine
2018 StandoutNobel
Perspectives on HCV: Current Therapeutic Regimens and Drug–Drug Interactions
2017
Viral Quasispecies Evolution
2012
Diverse CD81 Proteins Support Hepatitis C Virus Infection
2006 StandoutNobel
Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment
2017 StandoutNobel
Chemical Chaperones Reduce ER Stress and Restore Glucose Homeostasis in a Mouse Model of Type 2 Diabetes
2006 StandoutScience
Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus
2016 StandoutNobel
Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants
2009 StandoutNobel
Characterization of Hepatitis C Virus Core-Specific Immune Responses Primed in Rhesus Macaques by a Nonclassical ISCOM Vaccine
2001 StandoutNobel
Works of Daniel Forton being referenced
Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement
2012
Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C
1999
Cerebral dysfunction in chronic hepatitis C infection
2003
Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection
2015
Cerebral microglial activation in patients with hepatitis c: in vivo evidence of neuroinflammation
2011
Hepatitis C virus E2 and NS5A region variability during sequential treatment with two interferon‐α preparations
2003
Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease
2002
Central nervous system changes in hepatitis C virus infection
2006
In vivo imaging of cerebral “peripheral benzodiazepine binding sites” in patients with hepatic encephalopathy
2005
Extrahepatic Morbidity and Mortality of Chronic Hepatitis C
2015
Fatigue and primary biliary cirrhosis: association of globus pallidus magnetisation transfer ratio measurements with fatigue severity and blood manganese levels
2004
Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: Final results from the STEPS trial
2013
Quality of life and cognitive function in chronic hepatitis C – what to measure?
2003
Identification of Unique Hepatitis C Virus Quasispecies in the Central Nervous System and Comparative Analysis of Internal Translational Efficiency of Brain, Liver, and Serum Variants
2004
Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus–infected patients treated with direct‐acting antivirals
2017
LO5 : Sofosbuvir + peginterferon/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: The boson study
2015